CVRX - NASDAQ
CVRx, Inc.
$5.39
-1.3%CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
At a Glance
Live SnapshotCVRx, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
CVRx, Inc. Income Statement
CVRX • NASDAQ
| CVRx, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
56.7M | 51.3M | 39.3M | 22.5M | 13M | 6.1M | 6.3M | |
GROSS PROFIT | |||||||
(8.3M) | (8.3M) | (6.3M) | (5M) | (3.6M) | (1.4M) | (1.7M) | |
48.3M | 43M | 33M | 17.5M | 9.4M | 4.6M | 4.6M | |
OPERATING INCOME | |||||||
(99.6M) | (102.4M) | (76.1M) | (60M) | (35.4M) | (16.1M) | (14.8M) | |
(88.5M) | (91.3M) | (64.5M) | (50M) | (27.9M) | (9.7M) | (6.1M) | |
(11.1M) | (11.1M) | (11.6M) | (10M) | (7.5M) | (6.4M) | (8.7M) | |
-51.3M | -59.5M | -43.1M | -42.5M | -26M | -11.5M | -10.2M | |
PRE-TAX INCOME | |||||||
(5.8M) | (4.4M) | (1.8M) | (165K) | (2.2M) | (2.5M) | (1.7M) | |
-5.8M | -4.4M | -1.8M | -165K | -2.2M | -2.5M | -1.7M | |
-2.1M | -420K | 2.1M | 1.2M | -17M | -2.5M | -4.4M | |
-53.3M | -59.9M | -41.1M | -41.3M | -43M | -14M | -14.6M | |
NET INCOME | |||||||
(18K) | (55K) | (147K) | (109K) | (91K) | (85K) | (73K) | |
-53.3M | -60M | -41.2M | -41.4M | -43.1M | -14.1M | -14.6M |
SEC Filings
CVRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 01, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | February 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 |
Related Guides
Continue your CVRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.